Buy Aceon | Cheap Aceon | Buy Aceon Online

cheapbag214s

Panel on Gene Patents Gets Emotional Legal Pad
Gene patenting is a touchy subject -- even for lawyers,[link widoczny dla zalogowanych].
On Monday night,[link widoczny dla zalogowanych], dozens of students,[link widoczny dla zalogowanych], faculty,[link widoczny dla zalogowanych], attorneys, venture capitalists and business owners gathered at Stanford Law School for a panel discussion about the gene patenting case Association for Molecular Pathology v. Mayo (now pending for the second time before the Supreme Court) and Classen v. Biogen.
Speaking for critics who believe patenting DNA is immoral and hurts patients was panelist Daniel Ravicher,[link widoczny dla zalogowanych], the executive director of the Public Patent Foundation, who represents AMP. For the proponents, Edward Reines,[link widoczny dla zalogowanych], a patent litigator at Weil Gotshal Manges,[link widoczny dla zalogowanych], argued patent protection promotes innovation and the large capital investments needed to develop drugs and diagnostic tools.
Much of their discussion centered on Myriad. In July,[link widoczny dla zalogowanych], a federal appeals court affirmed the right of Myriad Genetics to patent two genes linked to breast cancer, overturning a lower court ruling that threatened a key element of the biotech business. Ravicher announced that he was planning to file a cert. Supreme Court Tuesday. things got heated when Reines argued that Prometheus,[link widoczny dla zalogowanych], not Myriad, is the best case to hash out some of the legal ambiguities related to patenting genes because,[link widoczny dla zalogowanych], he said,[link widoczny dla zalogowanych], it was less emotional. Rather than getting caught up in emotional debates,[link widoczny dla zalogowanych], Reines said,[link widoczny dla zalogowanych], the focus should be on improving personalized medicine so that more people can be effectively treated for diseases such as cancer.
"That's the future of medicine," Reines said.
Ravicher countered that there wasn enough emotion involved in the debate over gene patenting. He then held up photographs of women he claimed had been denied cancer treatment because Myriad Genetics,[link widoczny dla zalogowanych], which had obtained patents on genes that are markers of increased risk for breast and ovarian cancers, refused to license the technology to other laboratories. That made the tests too expensive for many women.
Worried Ravicher was inciting too much emotion,[link widoczny dla zalogowanych], moderator Mark Lemley,[link widoczny dla zalogowanych], director of Stanford University program in law,[link widoczny dla zalogowanych], science, and technology and a partner at Durie Tangri,[link widoczny dla zalogowanych], told Ravicher to put the photos down. He refused, and defiantly continued to show several photographs of women. Reines sat stone faced,[link widoczny dla zalogowanych], reluctant to enter the fray. And after a few tense moments,[link widoczny dla zalogowanych], the discussion over patenting genes continued without further outburst.
相关的主题文章：

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]